Cost-effectiveness of lenalidomide

de Labry Lima Antonio Olry; Matas Hoces Antonio; Gimeno Ballester Vicente; Rios Sanchez Esmeralda; Alegre del Rey Emilio Jesus

首页> 外文期刊>Bone marrow transplantation >Cost-effectiveness of lenalidomide

【24h】

Cost-effectiveness of lenalidomide

机译：Lenalidomide的成本效益

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Bone marrow transplantation》 |2020年第5期|共2页
作者
de Labry Lima Antonio Olry; Matas Hoces Antonio; Gimeno Ballester Vicente; Rios Sanchez Esmeralda; Alegre del Rey Emilio Jesus;
展开▼
作者单位

Escuela Andaluza Salud Publ Granada Spain;

Ctr Andaluz Informac Medicamento CADIME Granada Spain;

Univ Hosp Miguel Servet Serv Pharm Zaragoza Spain;

Puerto Real Univ Hosp Serv Pharm Cadiz Spain;

Puerto Real Univ Hosp Serv Pharm Cadiz Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment [J] . GarrisonJr.L.P., WangS.-T., HuangH., The oncologist . 2013,第1期

机译：硼替佐米+美法仑+泼尼松与沙利度胺+美法仑+泼尼松或来那度胺+美法仑+泼尼松联合来那度胺维持治疗在美国初治多发性骨髓瘤的成本效益
2. Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data [J] . M. Campioni, I. Agirrezabal, R. Hajek, The European journal of health economics: HEPAC : health economics in prevention and care . 2020,第2期

机译：使用Registry数据与Lenalalomide和DexameDhisone联合多种骨髓瘤的现实世界成本效果的方法和结果
3. Cost-effectiveness of lenalidomide [J] . de Labry Lima Antonio Olry, Matas Hoces Antonio, Gimeno Ballester Vicente, Bone marrow transplantation . 2020,第5期

机译：Lenalidomide的成本效益
4. Quantitative Structure-Activity Relationship Model of Lenalidomide Analogues as TNF-Inhibitors [C] . Li, Xiao-Li, Li, Min, Ke, Zheng, International conference on computational and information sciences . 2013

机译：来那度胺类似物作为TNF抑制剂的定量构效关系模型
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment [O] . Louis P. Garrison Jr., Si-Tien Wang, Hui Huang, 2013

机译：硼替佐米加美法仑和泼尼松与沙利度胺加美法仑和泼尼松或来那度胺加美法仑和泼尼松联合来那度胺持续维持治疗的美国多发性骨髓瘤的初始治疗的成本效益
7. PSY19 THE COST-EFFECTIVENESS OF BORTEZOMIB PLUS MELPHALAN AND PREDNISONE VERSUS LENALIDOMIDE PLUS MELPHALAN AND PREDNISONE WITH CONTINUOUS LENALIDOMIDE MAINTENANCE TREATMENT FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES [O] . Wang S.T., Huang H., Ba-mancini A., 2011

机译：PSY19在美国初次治疗多发性骨髓瘤的硼替佐米加美法仑和雷地松对苯丙二胺加美法兰和雷地松联合连续利马来胺的维持治疗的成本效益

Cost-effectiveness of lenalidomide

著录项

相似文献

相关主题

期刊订阅